A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Puma Biotechnology, Inc.
- ID
- NCT06369285
- Phase
- Phase 2 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- Expecting 150 study participants
- Last Updated